Biogen to expand portfolio with $7.3bn acquisition of Reata Pharmaceuticals

By on    Pharma Industry News  

Biogen to expand portfolio with $7.3bn acquisition of Reata Pharmaceuticals

Biogen Inc. (Nasdaq: BIIB) is set to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA) for $172.5 per share in cash, amounting to an enterprise value of approximately $7.3 billion. This significant step forward was announced by both companies, showcasing Biogen’s dedication to expand its presence in the treatment of serious neurologic diseases. Reata Pharmaceuticals, recognized for […]

Reata Pharmaceuticals gets Skyclarys FDA approval for Friedreich’s Ataxia

By on    Pharma Industry News  

Reata Pharmaceuticals gets Skyclarys FDA approval for Friedreich’s Ataxia

Reata Pharmaceuticals has secured the approval of the US Food and Drug Administration (FDA) for Skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia, a neuromuscular disease. Skyclarys is an oral, once-daily medication indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older in the US. Patients are recommended to […]